Sugi Predict

Sugi Predict / Compounds / SCHEMBL1096790

SCHEMBL1096790

SCHEMBL1096790

CC1(C)O[C@H]2O[C@H]([C@H]3COC(C)(C)O3)[C@H](OCc3ccccc3)[C@H]2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PDPK1 O15530 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ TMEM97 Q5BJF2 2/20 0.33
▸ SIGMAR1 Q99720 2/20 0.33
▸ ELANE P08246 2/20 0.32
▸ GSTP1 P09211 2/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ CTSV O60911 1/20 0.31
▸ CTSL P07711 1/20 0.31
▸ CTSB P07858 1/20 0.31
▸ CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13204993 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL4546295 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL4336848 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL13953494 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL2312455 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL23989231 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL22892189 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL22236621 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL22335647 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A
SCHEMBL18671587 1.00 CA1 (0.53) CA1CA2CA9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747261-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS Accutar Biotechnology Inc. (US) 2026-05-27 — — EP disclosed
US-12338248-B2 Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors ACCUTAR BIOTECHNOLOGY INC. (US) 2025-06-24 — — US disclosed
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors ACCUTAR BIOTECHNOLOGY INC. 2025-03-13 — — US disclosed
WO-2025024388-A1 AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2025-01-30 — — WO disclosed
WO-2023011597-A1 LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS Hepagene Therapeutics (HK) Limited (CN) 2023-02-09 — — WO disclosed
EP-2850092-B1 TRICYCLIC NUCLEIC ACID ANALOGS IONIS PHARMACEUTICALS INC (US) 2017-03-01 — — EP disclosed
EP-1015469-B2 BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES EXIQON AS (DK) 2015-11-18 — — EP disclosed
US-20150065700-A1 METHOD FOR PREPARING 3-O-BENZYL-1,2-O-ISOPROPYLIDENE-A-L-FURAN IDOSE ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2015-03-05 — — US disclosed
EP-2818476-A1 METHOD FOR PREPARING 3-O-BENZYL-1,2-O-ISOPROPYLIDENE- -L-FURAN IDOSE Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) 2014-12-31 — — EP disclosed
US-8846880-B2 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity of the inflammatory response Centre National de la Recherche Scientifique—CNRS— (FR) 2014-09-30 — — US disclosed
US-6670461-B1 Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. EXIQON A/S (DK) 2003-12-30 — — US disclosed
US-20030134808-A1 Oligonucleotide analogues WENGEL JESPER (DK) 2003-07-17 — — US disclosed
US-5248779-A Synthesis of nojirimycin derivatives MONSANTO COMPANY (US) 1993-09-28 — — US disclosed
EP-0439444-A2 Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors MONSANTO COMPANY (US) 1991-07-31 — — EP disclosed
US-5013842-A Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors MONSANTO COMPANY (US) 1991-05-07 — — US disclosed
EP-0423099-A1 Synthesis of nojirimycin derivatives Monsanto Company (US) 1991-04-17 — — EP disclosed
EP-0416396-A2 Tetrasaccharides and process for their preparation MERCK PATENT GmbH (DE) 1991-03-13 — — EP disclosed
US-4579582-A REDUCES THE GERMINATION OR EARLY GROWTH OF GRASSES CHEVRON RESEARCH COMPANY (US) 1986-04-01 — — US disclosed
US-4429119-A PLANT GROWTH REGULATORS CHEVRON RESEARCH COMPANY (US) 1984-01-31 — — US disclosed
US-4177344-A FIBRINOLYTIC, ANTICOAGULANT CIBA-GEIGY CORPORATION (US) 1979-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065700-A1 METHOD FOR PREPARING 3-O-BENZYL-1,2-O-ISOPROPYLIDENE-A-L-FURAN IDOSE GALE, OGA, SI CA1 1719/4885CA2 1601/4885CA9 1260/4885
US-12338248-B2 Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors CDK6, CDK2, CDK8 CA1 4670/4885CA2 4287/4885CA9 4467/4885
US-20030134808-A1 Oligonucleotide analogues TARBP1, DCLRE1B, ADAR CA1 3784/4885CA2 4503/4885CA9 3658/4885
US-20250084095-A1 Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors CDK6, CDK2, CDK8 CA1 4670/4885CA2 4287/4885CA9 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback